S-1MEF 1 d880651ds1mef.htm S-1MEF S-1MEF

As filed with the Securities and Exchange Commission on January 29, 2025.

Registration No. 333-   

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM S-1

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

 

 

Beta Bionics, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   3841   47-5386878

(State or other jurisdiction of

incorporation or organization)

 

(Primary Standard Industrial

Classification Code Number)

 

(I.R.S. Employer

Identification No.)

Beta Bionics, Inc.

11 Hughes, Suite 100

Irvine, CA

(619) 937-2754

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

Sean Saint

President and Chief Executive Officer

Beta Bionics, Inc.

11 Hughes

Irvine, California 92618

(949) 427-7785

(Name, address, including zip code, and telephone number, including area code, of agent for service)

Copies to:

Carlos Ramirez

Mark Weeks

Charles S. Kim

Cooley LLP

10265 Science Center Drive

San Diego, California 92121

(858) 550-6000

 

Nathan Ajiashvili

Ross McAloon

Matthew T. Bush

Latham & Watkins LLP

1271 Avenue of the Americas

New York, New York 10020

(212) 906-1200

 

 

Approximate date of commencement of proposed sale to the public: As soon as practicable after this Registration Statement becomes effective.

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933 check the following box: ☐

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☒ (333-284147)

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer      Accelerated filer  
Non-accelerated filer      Smaller reporting company  
     Emerging growth company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

The Registration Statement shall become effective upon filing in accordance with Rule 462(b) promulgated under the Securities Act of 1933, as amended.

 

 

 


EXPLANATORY NOTE AND INCORPORATION BY REFERENCE

This Registration Statement is being filed pursuant to Rule 462(b) under the Securities Act of 1933, as amended (the “Securities Act”) by Beta Bionics, Inc. (the “Registrant”), for the sole purpose of increasing the aggregate number of shares of common stock offered and registered by the Earlier Registration Statement (as defined below) by 2,300,000 shares, 300,000 of which are subject to purchase upon exercise of the underwriters’ option to purchase additional shares of the Registrant’s common stock. The contents of the Registration Statement on Form S-1, as amended (File No. 333-284147), including all exhibits thereto (the “Earlier Registration Statement”), filed by the Registrant with the Securities and Exchange Commission (the “Commission”) pursuant to the Securities Act, which was declared effective by the Commission on January 29, 2025, are incorporated by reference into this Registration Statement. The additional shares of common stock that are being registered for issuance and sale pursuant to this Registration Statement are in an amount and at a price that together represent no more than 20% of the maximum aggregate offering price set forth in Exhibit 107 of the Earlier Registration Statement.

The required opinion and consents are listed on an Exhibit Index attached hereto and filed herewith.

EXHIBIT INDEX

 

Exhibit

No.

  

Exhibit Index

  5.1    Opinion of Cooley LLP.
 23.1    Consent of Independent Registered Public Accounting Firm.
 23.4    Consent of Cooley LLP (included in Exhibit 5.1).
 24.1*    Power of Attorney.
107    Filing Fee Table.

 

*

Previously filed on the signature page to the Registrant’s Registration Statement on Form S-1 (File No. 333-284147), originally filed with the Securities and Exchange Commission on January 6, 2025 and incorporated by reference herein.


SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Irvine, California on January 29, 2025.

 

BETA BIONICS, INC.
By:  

/s/ Sean Saint

  Sean Saint
  President and Chief Executive Officer

Pursuant to the requirements of the Securities Act of 1933, this Registration Statement on Form S-1 has been signed by the following persons in the capacities held on the dates indicated.

 

Signature

  

Title

 

Date

/s/ Sean Saint

Sean Saint

  

President, Chief Executive Officer and

Director

(Principal Executive Officer)

  January 29, 2025

/s/ Stephen Feider

Stephen Feider

  

Chief Financial Officer

(Principal Financial and Accounting Officer)

  January 29, 2025

*

Adam Lezack

   Chairperson of the Board of Directors   January 29, 2025

*

Sean Carney

   Member of the Board of Directors   January 29, 2025

*

Dan Dearen

   Member of the Board of Directors   January 29, 2025

*

Christy Jones

   Member the Board of Directors   January 29, 2025

*

Maria Palasis, Ph.D.

   Member of the Board of Directors   January 29, 2025

 

*By:  

/s/ Sean Saint

  Sean Saint
  Attorney-in-Fact